These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8033283)

  • 1. Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte/macrophage-like U937 cells.
    Korth R; Zimmermann K; Richter WO
    Chem Phys Lipids; 1994 Apr; 70(2):109-19. PubMed ID: 8033283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the PAF receptor in human monocyte-derived macrophages is downregulated by oxidized LDL: relevance to the inflammatory phase of atherogenesis.
    Stengel D; Antonucci M; Arborati M; Hourton D; Griglio S; Chapman MJ; Ninio E
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):954-62. PubMed ID: 9157961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
    Terashita Z; Imura Y; Nishikawa K
    Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L; Floch A; Cavero I
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low density lipoproteins downregulate LPS-induced platelet-activating factor receptor expression in human monocyte-derived macrophages: implications for LPS-induced nuclear factor-kappaB binding activity.
    Hourton D; Stengel D; Chapman MJ; Ninio E
    Eur J Biochem; 2001 Aug; 268(16):4489-96. PubMed ID: 11502209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
    Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
    Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
    Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.
    Herbert JM; Laplace MC; Maffrand JP
    Biochem Pharmacol; 1993 Jan; 45(1):51-8. PubMed ID: 8381007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
    Herbert JM; Laplace MC; Cailleau C; Maffrand JP
    J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets.
    Nunez D; Kumar R; Hanahan DJ
    Arch Biochem Biophys; 1989 Aug; 272(2):466-75. PubMed ID: 2502069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist.
    Leitinger N; Watson AD; Faull KF; Fogelman AM; Berliner JA
    Adv Exp Med Biol; 1997; 433():379-82. PubMed ID: 9561175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
    Proudfoot JM; Croft KD; Puddey IB; Beilin LJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):846-53. PubMed ID: 12626661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long time incubation of monocytic U 937 cells with LDL increases specific paf-acether binding and the cellular acetylhydrolase activity.
    Korth R; Middeke M
    Chem Phys Lipids; 1991 Oct; 59(3):207-13. PubMed ID: 1804564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three paf-acether receptor antagonist ginkgolides.
    Korth R; Nunez D; Bidault J; Benveniste J
    Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity.
    Shukla SD; Morrison WJ; Klachko DM
    Transfusion; 1989; 29(6):528-33. PubMed ID: 2546298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin.
    Herbert JM; Castro-Faria-Neto HC; Barbosa-Filho JM; Cordeiro RS; Tibiriça E
    J Lipid Mediat Cell Signal; 1997 Sep; 17(1):1-14. PubMed ID: 9302650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.